PURPOSE: To assess the effect of two high-oxygen epi-on PiXL treatments for low-grade myopia. METHODS: This prospective, randomized, intra-individually comparing, single-masked study included 23 healthy volunteers (46 eyes) aged 18-35 years with mild myopia, -0.75 to -2.50 D manifest refractive spherical equivalent (MRSE). One eye was randomized to a 4.0-mm homogenous treatment zone and the fellow eye to a 4.0-mm annular zone (16:40 min at 30 mW/cm2 , fluence 15 J/cm2 ). Uncorrected distance visual acuity (UDVA), MRSE, best spectacle-corrected visual acuity (BSCVA), Scheimpflug light scattering depths, mean keratometry (Kmean ) and endothelial cell count (ECC) were assessed through 24 months. RESULTS: Similar improvements in UDVA were seen for the homogeneous and annular protocols at 1 month: -0.52 (-0.59, -0.39) and -0.49 (-0.59, -0.39) logMAR, respectively (medians and interquartile ranges, IQR), p = 0.91, and MRSE: +1.0 D (0.94, 1.31) and +1.0 D (0.69, 1.25), p = 0.17. Light scattering depths were 496 (465, 527) and 349 (247, 378) µm, respectively, and the reduction in mean keratometry was -0.8 D (-1.1, -0.7) and 0 D (-0.1, 0.1), p < 0.001. The treatment effect remained stable throughout 24 months. At 1 week, the participants reported less ocular discomfort with the annular protocol. No reductions were seen in BSCVA or ECC. No adverse events were reported. CONCLUSION: PiXL can reduce low-grade myopia and improve uncorrected vision in healthy eyes. The initial ocular discomfort may be reduced with an annular treatment zone. Further studies are needed to optimize PiXL treatment parameters.
PURPOSE: To assess the effect of two high-oxygen epi-on PiXL treatments for low-grade myopia. METHODS: This prospective, randomized, intra-individually comparing, single-masked study included 23 healthy volunteers (46 eyes) aged 18-35 years with mild myopia, -0.75 to -2.50 D manifest refractive spherical equivalent (MRSE). One eye was randomized to a 4.0-mm homogenous treatment zone and the fellow eye to a 4.0-mm annular zone (16:40 min at 30 mW/cm2 , fluence 15 J/cm2 ). Uncorrected distance visual acuity (UDVA), MRSE, best spectacle-corrected visual acuity (BSCVA), Scheimpflug light scattering depths, mean keratometry (Kmean ) and endothelial cell count (ECC) were assessed through 24 months. RESULTS: Similar improvements in UDVA were seen for the homogeneous and annular protocols at 1 month: -0.52 (-0.59, -0.39) and -0.49 (-0.59, -0.39) logMAR, respectively (medians and interquartile ranges, IQR), p = 0.91, and MRSE: +1.0 D (0.94, 1.31) and +1.0 D (0.69, 1.25), p = 0.17. Light scattering depths were 496 (465, 527) and 349 (247, 378) µm, respectively, and the reduction in mean keratometry was -0.8 D (-1.1, -0.7) and 0 D (-0.1, 0.1), p < 0.001. The treatment effect remained stable throughout 24 months. At 1 week, the participants reported less ocular discomfort with the annular protocol. No reductions were seen in BSCVA or ECC. No adverse events were reported. CONCLUSION: PiXL can reduce low-grade myopia and improve uncorrected vision in healthy eyes. The initial ocular discomfort may be reduced with an annular treatment zone. Further studies are needed to optimize PiXL treatment parameters.
Authors: Cosimo Mazzotta; Ashraf Armia Balamoun; Ayoub Chabib; Miguel Rechichi; Francesco D'Oria; Farhad Hafezi; Simone Alex Bagaglia; Marco Ferrise Journal: J Clin Med Date: 2022-08-27 Impact factor: 4.964